Frankfurt
27.06.25 | 09:59
8,300 Euro
-2,35 % -0,200
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 8,300 | 8,550 | 28.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Fr | ASCENTAGE-B (06855): FURTHER GRANT OF AWARDS UNDER THE 2021 RSU SCHEME AND THE 2022 RSU SCHEME | - | HKEx | ||
| 18.06. | HSI Down 269 pts; HSTI Down 77 pts; MEITUAN Down over 3%; CHINAHONGQIAO, UNITEDENERGY GP, ASCENTAGE, OCUMENSION-B, SHANGHAI IND H Hit New Highs; Market Turnover Rises | 4 | AASTOCKS | ||
| 18.06. | HSI Down 281 pts; HSTI Down 83 pts; MEITUAN Down over 3%; UNITEDENERGY GP, ASCENTAGE, FORTUNE REIT, GUANGDONG INV Hit New Highs | 4 | AASTOCKS | ||
| 16.06. | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA RELEASES LATEST RESULTS FROM MULTIPLE CLINICAL STUDIES IN 2025 EUROPEAN HEMATOLOGY ASSOCIATION ... | - | HKEx | ||
| ASCENTAGE PHARMA GROUP Aktie jetzt für 0€ handeln | |||||
| 16.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL | 138 | GlobeNewswire (Europe) | ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers... ► Artikel lesen | |
| 11.06. | CICC Lifts ASCENTAGE-B's TP to HKD69 on Impressive APG-2575 Data | 2 | AASTOCKS | ||
| 10.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 10.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress | 1 | GlobeNewswire (USA) | ||
| 03.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 03.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors | 66 | GlobeNewswire (Europe) | ROCKVILLE, Md. and SUZHOU, China, June 02, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers... ► Artikel lesen | |
| 03.06. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report | 1 | GlobeNewswire (USA) | ||
| 23.05. | ASCENTAGE PHARMA GROUP INTERNATIONAL: Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025 | 55 | GlobeNewswire (Europe) | ROCKVILLE, Md. and SUZHOU, China, May 22, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers... ► Artikel lesen | |
| 23.05. | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA PRESENTS RESULTS FROM TWO CLINICAL STUDIES AT 2025 ASCO ANNUAL MEETING, INCLUDING AN ORAL ... | 2 | HKEx | ||
| 20.05. | ASCENTAGE PHARMA GROUP INTERNATIONAL - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 19.05. | ASCENTAGE-B (06855): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 19, 2025 | - | HKEx | ||
| 30.04. | ASCENTAGE-B (06855): SECOND PROXY FORM FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MAY 19, 2025 | - | HKEx | ||
| 30.04. | ASCENTAGE-B (06855): SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 30.04. | ASCENTAGE-B (06855): SUPPLEMENTAL CIRCULAR - (1) PROPOSED AMENDMENTS TO THE 2021 RSU SCHEME; (2) PROPOSED AMENDMENTS TO THE 2022 RSU SCHEME; (3) PROPOSED ... | - | HKEx | ||
| 29.04. | AACR 2025: Quintet of investigational oncological drugs puts Ascentage on positive ascent | - | pharmaphorum |
1 2 3 4 5 Weiter >>
84 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
| CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
| QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
| SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
| KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
| ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| EVOTEC | 7,138 | -0,81 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
| BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
| CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |
Das Unternehmen ASCENTAGE PHARMA GROUP INTERNATIONAL kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,200 (-2,35 %) liegt der Kurs bei 8,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCENTAGE PHARMA GROUP INTERNATIONAL finden Sie auf Wallstreet Online.